Protocol summary

Study aim
Evaluating efficacy of Kelofan syrup on pulmonary & other clinical and laboratory manifestations of patients with probable or confirmed COVID-19
Design
This study is a randomized controlled clinical trial on hospitalized patients with probable or confirmed COVID-19. Individuals with eligibility criteria will be randomly divided into two groups of intervention and control, and 30 patients will be enrolled in each group. The study is three-blinded and the patient, the nurse giving the medication, the data collector, and the data analyzer are not aware of the type of assignment.
Settings and conduct
This study will be carried out at Imam Khomeini Hospital, one of the hospitals affiliated to Ardabil University of Medical Sciences. This hospital has been assigned for COVID-19 patients. This research will be carried out from May to July of 2020.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients over 18 years old hospitalized with or probable of COVID-19 based on Radiological findings or Positive PCR test according to the instructions of the Ministry of Health; Clinically classified as moderate and severe, no need for intubation; written and informed satisfaction of patients Non-inclusion: Liver, kidney and heart failure; History of allergies to medicinal herbs; Immunodeficiency; Uncontrplled Hypertension; Uncontrolled Diabetes; Alcohol or drug addiction
Intervention groups
Patients are receiving a herbal formulation (Kelofan syrup) in form of a syrup at a dose of 7.5 cc two times a day for a maximum of seven days, in addition to standard treatment.
Main outcome variables
Respiratory rate per minute; O2 Saturation

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20200405046960N2
Registration date: 2020-05-19, 1399/02/30
Registration timing: registered_while_recruiting

Last update: 2020-05-19, 1399/02/30
Update count: 0
Registration date
2020-05-19, 1399/02/30
Registrant information
Name
ramin nasimi doost azgomi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 45 3352 0365
Email address
r.nasimi@arums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-05-17, 1399/02/28
Expected recruitment end date
2020-07-05, 1399/04/15
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product on pulmonary & other clinical and laboratory manifestations of patients with or probable of covid-19
Public title
Efficacy of Kelofan syrup on COVID-19
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients over 18 years old Hospitalized patients withprobable or confirmed COVID-19 based on radiologicalfindings or positive PCR test according to the instructions22of the Ministry of Health Clinically classified as moderateand severe, no need for intubation Written and informedsatisfaction of patients
Exclusion criteria:
Liver, kidney and heart failure History of allergies to medicinal herbs Immunodeficiency Uncontrolled hypertension Uncontrolled diabetes Alcohol or drug addiction Patients with transplanted organs Cor Pulmonel Patients Takinganticoagulants, antiarrhythmics, antihypertensives, corticosteroids and immunosuppressants Pregnancy Breast feeding
Age
From 18 years old
Gender
Both
Phase
2-3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 60
Randomization (investigator's opinion)
Randomized
Randomization description
Samples will be randomly assigned to four blocks using Random Allocation Software. Blocking and allocation sequences for concealment will be done by the non-involved researcher (Allocation Concealment).The sample allocation ratio will be Allocation 1:1 and will be divided into two groups of receiving Iranian medicine products and control group (Assignment). Then based on blocks and allocation sequences medication will be given to patients
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, patients will be informed by consent form that they would either be in the intervention group or the control group, but they won't be aware of the type of medication. Nurses who supply the drug are also unaware of its content because the appearance, taste, color, and prescription of the drug are similar, but the code on the drug will be different. The written codes on the drugs are random and only the non-involved researcher is aware of the drug type and the inserted code on it. The patient data collector and the project statistical partner are also unaware of the type of intervention. As the control group uses placebo, which is similar in appearance, taste, color, and prescription, patients will be unaware of the type of drug being administered.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

1

Registry name
Secondary trial Id
Registration date
empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Ardabil University of Medical Sciences
Street address
Ardabil University of Medical Sciences; Daneshgah street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Approval date
2020-04-05, 1399/01/17
Ethics committee reference number
IR.ARUMS.REC.1399.009

Health conditions studied

1

Description of health condition studied
Covid-19
ICD-10 code
U07.1
ICD-10 code description
COVID19, virus identified

2

Description of health condition studied
Covid-19
ICD-10 code
U07.2
ICD-10 code description
COVID19, virus not identified

Primary outcomes

1

Description
Oxygen saturation
Timepoint
Clinical examination and Pulse Oximetry before starting intervention and regularly during hospitalized
Method of measurement
Pulse Oximeter

2

Description
Respiratory Rate
Timepoint
Clinical examination before starting intervention and regularly during hospitalized
Method of measurement
Respiratory Count

Secondary outcomes

1

Description
C-reactive protein
Timepoint
Intravenous blood testing before starting intervention and during hospitalized
Method of measurement
Venous blood test

2

Description
Lymphocytes
Timepoint
Intravenous blood testing before starting intervention and during hospitalized
Method of measurement
Venous blood test

3

Description
White Cell blood count
Timepoint
Intravenous blood testing before starting intervention and during hospitalized
Method of measurement
Venous blood test

4

Description
Liver enzymes
Timepoint
Intravenous blood testing before starting intervention and during hospitalized
Method of measurement
Venous blood test

5

Description
Cough
Timepoint
Clinical examination before starting intervention and regularly during treatment
Method of measurement
Patient follow up

6

Description
Fever
Timepoint
Clinical examination before starting intervention and regularly during treatment
Method of measurement
Thermometer

Intervention groups

1

Description
Intervention group: In the intervention group, in addition to the standard treatment, medicinal herbal products will be prescribed.The drug will be given in syrup form. The syrup will contain the following medicinal herbs: Nepeta bracteata، Adiantum capillus veneris، Glycyrrhiza glabra, Foeniculum vulgare، Viola odorata, Ziziphus jujube, Malva sylvestris, Nigella sativa . The intervention group will receive 7.5 cc of Kelofan syrup every 12 hours one week.
Category
Treatment - Drugs

2

Description
Control group: This group receive routine treatments for COVID-19 disease and placebo. Placebo will be given as an oral syrup, two servings a day. For the placebo syrup, of stevia, authorized oral dyes are used to make the color and taste relatively similar to the original drug.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Imam Khomeini Hospital
Full name of responsible person
Ramin Nasimi Doost Azgomi
Street address
Emam Khomeini Hospital, Baradaran Shahid Noei Aghdam street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3142 2529
Email
modir7060@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Dr.Shahab Bohlooliا
Street address
Ardabil University of Medical Sciences; Daneshgah street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3353 4776
Email
shahab.bohlooli@arums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ardabil University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Ramin Nasimi Doost Azgomi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Ardabil University of Medical Sciences; Daneshgah street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3142 2529
Email
modir7060@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Ramin Nasimi Doost Azgomi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Ardabil University of Medical Sciences; Daneshgah street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3142 2529
Email
modir7060@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Ramin Nasimi Doost Azgomi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Ardabil University of Medical Sciences; Daneshgah street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3142 2529
Email
modir7060@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...